Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($19.28) EPS for the quarter, missing the consensus estimate of ($9.91) by ($9.37), Zacks reports. The company had revenue of $2.21 million during the quarter, compared to analysts’ expectations of $3.50 million.
Tonix Pharmaceuticals Stock Performance
NASDAQ:TNXP opened at $0.45 on Monday. The stock has a market cap of $7.81 million, a P/E ratio of 0.00 and a beta of 2.12. The stock has a 50 day simple moving average of $0.78 and a 200 day simple moving average of $5.43. The company has a current ratio of 1.47, a quick ratio of 0.87 and a debt-to-equity ratio of 0.06. Tonix Pharmaceuticals has a 1-year low of $0.40 and a 1-year high of $32.32.
Analyst Upgrades and Downgrades
Several research analysts recently commented on TNXP shares. StockNews.com started coverage on Tonix Pharmaceuticals in a research report on Saturday. They set a “sell” rating for the company. Alliance Global Partners raised their price objective on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, July 22nd.
Tonix Pharmaceuticals Company Profile
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Featured Stories
- Five stocks we like better than Tonix Pharmaceuticals
- Energy and Oil Stocks Explained
- This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
- Upcoming IPO Stock Lockup Period, Explained
- Microvast vs. FREYR: Which Battery Stock Holds the Power?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Retail Earnings: Value, Caution, and Luxury in a Shifting Market
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.